Cerevel Therapeutics (CERE) Short Interest Ratio & Short Volume

Short interest is the volume of Cerevel Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 5,980,000 shares of CERE short. 6.83% of Cerevel Therapeutics' shares are currently sold short. Learn More on Cerevel Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CERE shares currently have a short interest ratio of 4.0. Learn More on Cerevel Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cerevel Therapeutics: Wolverine Trading LLC, Centiva Capital LP, Westchester Capital Management LLC, Walleye Trading LLC, LMR Partners LLP, Wolverine Asset Management LLC, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.83% of Cerevel Therapeutics' floating shares are currently sold short.

Cerevel Therapeutics saw a drop in short interest in July. As of July 15th, there was short interest totaling 5,980,000 shares, a drop of 9.3% from the previous total of 6,590,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Cerevel Therapeutics currently has issued a total of 182,200,000 shares. Some of Cerevel Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cerevel Therapeutics currently has a public float of 87,510,000 shares.

6.83% of Cerevel Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Cerevel Therapeutics: CNX Resources Co. (19.40%), Warrior Met Coal, Inc. (8.92%), Arch Resources, Inc. (8.95%), Hallador Energy (4.77%), Teva Pharmaceutical Industries Limited (1.60%), BeiGene, Ltd. (1.12%), United Therapeutics Co. (5.24%), Viatris Inc. (2.09%), Royalty Pharma plc (3.84%), Summit Therapeutics Inc. (2.31%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks.

Short selling CERE is an investing strategy that aims to generate trading profit from Cerevel Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cerevel Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CERE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CERE, twice per month. The most recent reporting period available is July, 15 2024.